Atara Biotherapeutics

EBV virus
#Atara Biotherapeutics #Biologics License Application (BLA) #Epstein-Barr virus #FDA #Pierre Fabre

Will this Atara Biotherapeutics drug be the first approved therapy of its kind? 

Atara Biotherapeutics has submitted a Biologics License Application (BLA) for Tabelecleucel (Tab-cel), a for treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) with the US Food and Drug Administration (FDA). There are currently no FDA approved therapies in this treatment setting.  It is indicated as… Read More

#News #Regulatory

T cell attacking cancer cell
#Atara Biotherapeutics #Epstein-Barr virus #EU #European Commission #Immunotherapy #Phase III trial #Pierre Fabre #T cell activation

First allogeneic T cell immunotherapy launched in EU

Pierre Fabre will commercialise and distribute the first approved allogeneic T cell immunotherapy in Europe following the transfer of the European Commission marketing authorisation of Ebvallo (tabelecleucel) from Atara Biotherapeutics.  Ebvallo is the only approved therapy for the treatment of relapsed or refractory Epstein‑Barr virus positive post‑transplant… Read More

#Business & Investment #News